LMO2 and gene therapy for severe combined immunodeficiency.

Documenti analoghi

• Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
  di: McCormack, M, et al.
  Pubblicazione: (2004)
• Null mutation of the Lmo4 gene or a combined null mutation of the Lmo1/Lmo3 genes causes perinatal lethality, and Lmo4 controls neural tube development in mice.
  di: Tse, E, et al.
  Pubblicazione: (2004)
• LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
  di: Hacein-Bey-Abina, S, et al.
  Pubblicazione: (2003)
• Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency
  di: Claudia A Montiel-Equihua, et al.
  Pubblicazione: (2009-12-01)
• Immune Reconstitution After Gene Therapy Approaches in Patients With X-Linked Severe Combined Immunodeficiency Disease
  di: Elena Blanco, et al.
  Pubblicazione: (2020-11-01)